03.04.2017 • News

Solvay Sells Polyolefin Compounds to Finproject

(c) Solvay
(c) Solvay

Solvay has sold another business as it pursues a transformation to a multi-specialty chemical group. This time, the Belgian company has agreed to sell its Italian polyolefin cross-linkable compounds business to family-owned firm Finproject for an undisclosed sum.

Based in Roccabianca, Parma, the division makes compounds that are used in wire and cable applications as well as in the pipe industry. It generated sales of €82 million in 2016.

Finproject, which is located in Morrovalle in Italy’s Marche region, makes injection molded foam, polyolefin-based compounds and PVC compounds that are used in footwear and other applications in the spa, automotive, furniture and safety industries.

The sale is expected to close in the second quarter of 2017, subject to the usual closing conditions.

Separately, Solvay has agreed to sell its 25.1% stake in National Peroxide to partner Wadia Group, boosting the Indian’s conglomerate shareholding to about 70.5%. Public shareholders hold about 29.5% of the Mumbai-listed company.

National Peroxide was formed in 1954 as a joint venture between the Wadia Group and Laporte and operates a 95.000 t/y hydrogen peroxide facility at Kalyan, Maharashtra. Solvay inherited the National Peroxide shareholding when it reorganized its Interox joint venture with Laporte back in 1992.

The transaction was due to complete by the end of March 2017.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.